Therapeutic angiogenesis-based strategy for peripheral artery disease

Peripheral artery disease (PAD) poses a great challenge to society, with a growing prevalence in the upcoming years. Patients in the severe stages of PAD are prone to amputation and death, leading to poor quality of life and a great socioeconomic burden. Furthermore, PAD is one of the major complica...

Full description

Saved in:
Bibliographic Details
Published inTheranostics Vol. 12; no. 11; pp. 5015 - 5033
Main Authors Han, Jingxuan, Luo, Lailiu, Marcelina, Olivia, Kasim, Vivi, Wu, Shourong
Format Journal Article
LanguageEnglish
Published Australia Ivyspring International Publisher Pty Ltd 01.01.2022
Ivyspring International Publisher
Subjects
Online AccessGet full text
ISSN1838-7640
1838-7640
DOI10.7150/thno.74785

Cover

More Information
Summary:Peripheral artery disease (PAD) poses a great challenge to society, with a growing prevalence in the upcoming years. Patients in the severe stages of PAD are prone to amputation and death, leading to poor quality of life and a great socioeconomic burden. Furthermore, PAD is one of the major complications of diabetic patients, who have higher risk to develop critical limb ischemia, the most severe manifestation of PAD, and thus have a poor prognosis. Hence, there is an urgent need to develop an effective therapeutic strategy to treat this disease. Therapeutic angiogenesis has raised concerns for more than two decades as a potential strategy for treating PAD, especially in patients without option for surgery-based therapies. Since the discovery of gene-based therapy for therapeutic angiogenesis, several approaches have been developed, including cell-, protein-, and small molecule drug-based therapeutic strategies, some of which have progressed into the clinical trial phase. Despite its promising potential, efforts are still needed to improve the efficacy of this strategy, reduce its cost, and promote its worldwide application. In this review, we highlight the current progress of therapeutic angiogenesis and the issues that need to be overcome prior to its clinical application.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
Competing Interests: The authors have declared that no competing interest exists.
These authors contributed equally to this manuscript.
ISSN:1838-7640
1838-7640
DOI:10.7150/thno.74785